News >

FDA Approves Nivolumab/Ipilimumab for Advanced HCC

Gina Columbus @ginacolumbusonc
Published: Wednesday, Mar 11, 2020

The FDA has granted an accelerated approval to the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of patients with hepatocellular carcinoma (HCC) who have received prior therapy with sorafenib (Nexavar).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication